4 year long term extension study for subject who participated in previous HS study
Inclusion Criteria
- Subjects who complete the study treatment period (52 weeks) in the “Core studies” (CAIN457M2301 or CAIN457M2302)
- Were on secukinumab treatment during the Treatment Period 2 of the core studies
Exclusion Criteria
- Subjects not expected to benefit from participation in the extension study, as assessed by the subject and investigator
Study Requirements
23 visits for up to 4 years